Investment
Features
FeesSafety
Academy
More
Pluang+

Compare HP Inc (HPQ) vs Revvity Inc (RVTY) Price & Performance

Revvity IncTrade

Price performance (Past 24H)

Key statistics

HP Inc vs Revvity Inc — how do they compare? HP Inc trades at $30.27 (market cap $29.25B), while Revvity Inc trades at $154.98 (market cap $16.98B). The key difference: HP Inc is the larger of the two by market cap, and HP Inc pays the higher dividend (3.7%). Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 69 Days and Revvity Inc for 12 Days on average.

HPQRVTY
Market Cap
$29.25B$16.98B
Volume
10,025,8061,456,900
Sector
TechnologyHealth
52-Week High
$35.48$157.36
52-Week Low
$18.20$82.26
Typical Hold Time
69 Days12 Days
Enterprise Value
$35.42B$19.30B
Dividend Yield
3.7%0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

HP Inc

HPQ is trading at $30.37, down 5.8% over the past 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $55.30 billion in 2025 and has beaten earnings estimates for the last three quarters. Recent news highlights HP's new product launches and a dividend payment scheduled for October 2026, though the stock faces pressure from a forecasted decline in PC sales for 2027.

The outlook for HPQ is mixed, with strong cash flow and consistent earnings beats providing support, but risks from a weakening PC market and high liabilities tempering upside. Analyst consensus is a hold with a price target of $25.75, suggesting cautious optimism amid industry headwinds. Investment opportunity lies in valuation metrics like a low P/E of 12.38, but execution risks remain key.

Revvity Inc

Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.

The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HPQ
73% Buy27% Sell
Avg holding period · 69 Days
RVTY
0% Buy100% Sell
Avg holding period · 12 Days

Top news

Latest headlines on both assets

About HP Inc

HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.

Read more on HPQ →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →